StemCell Institute

StemCell Institute AAQS

The The AAQS of StemCell Institute (7096.T) as of Oct 26, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

StemCell Institute has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock StemCell Institute in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The StemCell Institute AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2019
2.00 JPY
Jan 1, 2020
2.00 JPY
Jan 1, 2021
2.00 JPY
Jan 1, 2022
2.00 JPY
Jan 1, 2023
2.00 JPY
Jan 1, 2024
2.00 JPY
Jan 1, 2025
2.00 JPY
Jan 1, 2026
2.00 JPY
The StemCell Institute AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemCell Institute Stock analysis

What does StemCell Institute do? StemCell Institute KK operates a cell bank business segment focused on storing umbilical cord blood and cord tissue. The company collects umbilical cord blood from pregnant women through contracts with domestic cooperative hospitals, including university hospitals and obstetric clinics, then processes and stores the stem cells at its centers in Minato-ku, Tokyo, and Midori-ku, Yokohama. The firm generates revenue by charging customers for the separation, storage, and long-term preservation of stem cells, targeting expectant parents seeking future medical options. Its primary customer segment consists of pregnant women who sign storage contracts before childbirth. The company develops regenerative medicine products and new treatment methods, expanding its offerings beyond basic storage. It also invests in childbirth and childcare-related business areas, aligning with its core cell bank operations. StemCell Institute KK's revenue streams include fees for umbilical cord blood banking services and potential future sales of regenerative medicine products developed through its research and development efforts. StemCell Institute KK's business model centers on long-term storage contracts with customers, leveraging its cell processing and storage infrastructure. The firm's revenue is derived from upfront and recurring fees associated with the collection, processing, and preservation of stem cells from umbilical cord blood, with no mention of additional revenue sources such as partnerships or external investments in the provided description. StemCell Institute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemCell Institute stock

The AAQS of StemCell Institute is 2 in 2026.

On Eulerpool you can find the complete historical development of The AAQS StemCell Institute since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — StemCell Institute

All Key Metrics — StemCell Institute